Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029693 | 0.96 | ALDH1A1 (0.41) | ALDH1A1HTR2ACNR2ARTDP1 | |
| SCHEMBL13029715 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HTR2AARTDP1DRD2 | |
| SCHEMBL13029807 | 0.87 | ALDH1A1 (0.42) | ALDH1A1HTR2AARTDP1DRD2 | |
| SCHEMBL13029711 | 0.85 | CNR2 (0.39) | HTR2ACNR2ARDRD2MAPT | |
| SCHEMBL3416837 | 0.84 | PLA2G7 (0.46) | ALDH1A1AR | |
| SCHEMBL13029712 | 0.84 | CNR2 (0.38) | CNR2ARLMNA | |
| SCHEMBL13029713 | 0.84 | AR (0.36) | CNR2AR | |
| SCHEMBL13029710 | 0.84 | CNR2 (0.40) | ALDH1A1CNR2ARMEN1KMT2A | |
| SCHEMBL13029729 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HTR2AARTDP1LMNA | |
| SCHEMBL13029815 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HTR2AARTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255124-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | ALDH1A1 1164/4885HTR2A 1115/4885CNR2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.